Table 3.

Changes and discontinuations due to AEs, overall and by treatment line

	CT-P13 (N = 105)			Reference infliximab (N = 92)
	Overall (N = 105)	First line (n = 82)	Subsequent line (n = 23)	Overall (N = 92)	First line (n = 62)	Subsequent line (n = 30)
Patients changing biologic or discontinuing therapy due to an AE, n
Total	13	9	4	17	13	4
Changed biologic	8	5	3	5	4	1
Discontinued therapy	5	4	1	12	9	3
AEs leading to changed biologic or discontinued therapy, n
Changed biologic
Infusion/injection reaction	5	2	3	5	4	1
Uveitis	1	1
Skin rash	3	3		1		1
Discontinued therapy
Infusion/injection reaction	2	1	1	2	1	1
Mycobacterium tuberculosis infection pulmonary	1	1		4	4
Headache	2	2
Other infection				1		1
Transaminitis only				1	1
Psoriasis				1		1
Uveitis				1		1
Gastric ulcer				1	1
Acute kidney injury				1	1
Unknown				1	1

AE adverse event